CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 729 participants.

Also called NCT03296540

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 729 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03296540
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03296540. Randomized; no masking; primary purpose treatment. Start 2017-11-28 (actual); primary completion 2021-05-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI
Acronym
CompareCrush
Condition
Cardiovascular Diseases
Intervention (Drug)
Prasugrel (Crushed tablets)
Intervention (Drug)
Prasugrel (Integral tablets)
Lead sponsor
Maasstad Hospital (class: other)
Collaborator
MicroPort Orthopedics Inc. (class: industry)
Collaborator
Daiichi Sankyo (class: industry)
Collaborator
Research Maatschap Cardiologen Rotterdam Zuid (class: other)

Record details

Record id
cardio:ct-nct03296540
Content hash
b625a48e62862f871ce92b348c8637e95878cf4cc7deddc31ada2df65d2c4a88